Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: A systematic review and meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 12, 2013, Pages 1573-1584.e2

  Singh, Siddharth ^a   Fujii, Larissa L ^a   Murad, Mohammad Hassan ^a   Wang, Zhen ^a   Asrani, Sumeet K ^b   Ehman, Richard L ^a   Kamath, Patrick S ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Cirrhosis; Elastography; Outcomes; Prognosis

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER RISK; CHRONIC LIVER DISEASE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; ELASTOGRAPHY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW;

CANCER; CHRONIC LIVER DISEASE; CI; CIRRHOSIS; CLD; CONFIDENCE INTERVAL; ELASTOGRAPHY; HAZARD RATIO; HCC; HCV; HEPATIC VENOUS PRESSURE GRADIENT; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; HR; HVPG; LIVER STIFFNESS MEASUREMENT; LIVER TRANSPLANTATION; LSM; LT; MAGNETIC RESONANCE ELASTOGRAPHY; MELD; MODEL FOR END-STAGE LIVER DISEASE; MRE; OUTCOMES; PROGNOSIS; RELATIVE RISK; RR; TE; TRANSIENT ELASTOGRAPHY;

CHRONIC DISEASE; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER FAILURE; LIVER NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84887995212     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.034     Document Type: Article

References (43)

1. Asrani S.K., Larson J.J., Yawn B., et al. Underestimation of liver-related mortality in the United States. Gastroenterology 2013, 145:375-382.
2. Manos M.M., Leyden W.A., Murphy R.C., et al. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology 2008, 47:1150-1157.
3. Garcia-Tsao G., Friedman S., Iredale J., et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51:1445-1449.
4. Tsochatzis E.A., Bosch J., Burroughs A.K. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012, 56:1983-1992.
5. Ripoll C., Groszmann R., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007, 133:481-488.
6. Tsochatzis E.A., Gurusamy K.S., Ntaoula S., et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. JHepatol 2011, 54:650-659.
7. Castera L., Pinzani M., Bosch J. Non invasive evaluation of portal hypertension using transient elastography. JHepatol 2012, 56:696-703.
8. Shi K.Q., Fan Y.C., Pan Z.Z., et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013, 33:62-71.
9. Kim B.K., Park Y.N., Kim do Y., et al. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion 2012, 85:219-227.
10. Jung K.S., Kim S.U., Ahn S.H., et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011, 53:885-894.
11. Corpechot C., Carrat F., Poujol-Robert A., et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012, 56:198-208.
12. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. TheCochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
13. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W64.
14. Hayden J.A., van der Windt D.A., Cartwright J.L., et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013, 158:280-286.
15. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
16. Chene G., Thompson S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996, 144:610-621.
17. Cook M.B., Greenwood D.C., Hardie L.J., et al. Asystematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008, 103:292-300.
18. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Thompson S.G., Pocock S.J. Can meta-analyses be trusted?. Lancet 1991, 338:1127-1130.
20. Sterne J.A., Egger M., Smith G.D. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001, 323:101-105.
21. Akima T., Tamano M., Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res 2011, 41:965-970.
22. Fernandez-Montero J.V., Barreiro P., Vispo E., et al. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. AIDS 2013, 27:1129-1134.
23. Forestier J., Dumortier J., Guillaud O., et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010, 22:532-540.
24. Fung J., Lai C.L., Seto W.K., et al. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. JViral Hepat 2011, 18:738-744.
25. Chon Y.E., Jung E.S., Park J.Y., et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. JClin Gastroenterol 2012, 46:518-525.
26. Klibansky D.A., Mehta S.H., Curry M., et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. JViral Hepat 2012, 19:e184-e193.
27. Masuzaki R., Tateishi R., Yoshida H., et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009, 49:1954-1961.
28. Merchante N., Rivero-Juarez A., Tellez F., et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012, 56:228-238.
29. Robic M.A., Procopet B., Metivier S., et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. JHepatol 2011, 55:1017-1024.
30. Salmon D., Bani-Sadr F., Loko M.A., et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. JHepatol 2012, 56:862-868.
31. Tuma P., Jarrin I., Del Amo J., et al. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010, 24:745-753.
32. Vergniol J., Foucher J., Terrebonne E., et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011, 140:1970-1979.
33. Asrani S.K., Kamath P.S., Shah V.S., et al. Prediction of hepatic decompensation by magnetic resonance elastography among subjects with compensated cirrhosis. Hepatology 2012, 56:914A.
34. Calvaruso V.B.F., Simone F., Bavetta M.G., et al. Liver stiffness at baseline predicts decompensation and hepatocellular carcinoma in patients with compensated HCV cirrhosis. Hepatology 2012, 56:931A-932A.
35. Narita Y.G.T., Tsuzura H., Sato S., et al. Liver stiffness as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients receiving interferon-based antiviral therapy. Hepatology 2012, 56:451A.
36. Vu T.M.S.C., Mehta S., Higgins Y., et al. Baseline liver stiffness measured by transient elastography is independently associated with risk of end-stage liver disease and death among HIV/HCV co-infected adults. JHepatol 2011, 54:S470.
37. Kim B.K., Kim do Y., Han K.H., et al. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol 2011, 106:1654-1662. 1730.
38. Kim S.U., Lee J.H., Kim do Y., et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012, 7:e36676.
39. Koch A., Horn A., Duckers H., et al. Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Crit Care 2011, 15:R266.
40. Lindvig K., Mossner B.K., Pedersen C., et al. Liver stiffness and 30-day mortality in a cohort of patients admitted to hospital. Eur J Clin Invest 2012, 42:146-152.
41. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. JHepatol 2006, 44:217-231.
42. Vergniol J.B.J., Coutzac C., Bertrais S., et al. The evolution of liver stifffness predicts 4-year survival of patients with chronic hepatitis C. Hepatology 2012, 56:682A.
43. Altman D.G. Systematic reviews of evaluations of prognostic variables. BMJ 2001, 323:224-228.